



TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Change of Adviser

Alderley Park, 13 June 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on neuropsychiatry and oncology, announces that it has appointed Singer Capital Markets as its Nominated Adviser and Joint Broker with immediate effect.

-Ends-

Enquiries

TheraCryf plc

Dr Huw Jones, CEO

Toni Hänninen, CFO

Dr Helen Kuhlman, CBO

+44 (0)1625 315 090

enquiries@theracryf.com

Singer Capital Markets (NOMAD & Joint Broker)

Phil Davies / Oliver Platts / Patrick Weaver

+44 (0)20 7496 3000

Turner Pope Investments (Joint Broker)

James Pope / Andy Thacker

+44 (0)20 3657 0050

Vigo Consulting

Rozi Morris

+44 (0)20 7390 0230

theracryf@vigoconsulting.com

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma** and neurodevelopmental disorders [**orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has a number of industry partnerships with companies, including Stalicia SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF.